布加综合征患者动脉期高强化结节中廓清征诊断肝细胞癌的特异性低
这项回顾性研究纳入2000至2016年本院诊断布加综合征且MRI发现局灶性病变的49例患者(241个良性病变、12个肝细胞癌),评估廓清征鉴别良恶性的价值;廓清征诊断肝细胞癌特异性仅67%,近三分之一良性病变出现廓清,提示肝硬化患者的无创诊断标准不能外推至布加综合征患者。
要点
- 布加综合征患者中,29%(69/241)良性病变出现廓清征,肝细胞癌中为75%(9/12)。
- 动脉期高强化且≥1 cm的病变中,廓清征诊断肝细胞癌特异性为67%。
- 联合T1加权低信号可将特异性提高至100%,血清AFP>15 ng/ml特异性为95%。
核心结论
- 廓清征见于近三分之一良性病变,导致其诊断肝细胞癌特异性低至不可接受。
- 为肝硬化患者提出的无创诊断标准不能外推至布加综合征患者。
- 附加影像学表现和患者特征(包括血清甲胎蛋白水平)有助于判断布加综合征患者结节为肝细胞癌的概率。
研究设计与样本
- 回顾性研究,纳入2000至2016年本院诊断布加综合征且MRI发现局灶性病变的全部患者。
- 共49例患者(平均年龄35±12岁;女性34例[69%],男性15例[31%]),含241个良性病变和12个肝细胞癌病变。
- MRI图像由2名对病变性质不知情的放射科医生审阅。
主要发现
- 肝细胞癌患者年龄显著更大(平均44±16岁 vs 33±9岁,p=0.005),甲胎蛋白水平更高(中位数16 vs 3 ng/ml,p=0.007)。
- 廓清征见于9/12(75%)肝细胞癌和69/241(29%)良性病变(p<0.001)。
- 动脉期高强化且≥1 cm的143个病变中,52个(36%)显示廓清征(9个肝细胞癌和43个良性病变)。
- 在该亚组中,廓清征诊断肝细胞癌的特异性为67%。
- 添加T1加权低信号将特异性提高至100%;血清甲胎蛋白>15 ng/ml与95%特异性相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It remains unclear whether the classic imaging criteria for the non-invasive diagnosis of hepatocellular carcinoma (HCC) can be applied to chronic vascular liver diseases, such as Budd-Chiari syndrome (BCS). Herein, we aimed to evaluate the diagnostic value of washout for the discrimination between benign and malignant lesions in patients with BCS. METHODS: This retrospective study included all patients admitted to our institution with a diagnosis of BCS and focal lesions on MRI from 2000 to 2016. MRI images were reviewed by 2 radiologists blinded to the nature of the lesions. Patient and lesion characteristics were recorded, with a focus on washout on portal venous and/or delayed phases. Lesions were compared using Chi-square, Fisher's, Student's t or Mann-Whitney U tests. RESULTS: A total of 49 patients (mean age 35 ± 12 years; 34 women [69%] and 15 men [31%]) with 241 benign lesions and 12 HCC lesions were analyzed. Patients with HCC were significantly older (mean age 44 ± 16 vs. 33 ± 9 years, p = 0.005), with higher alpha-fetoprotein (AFP) levels (median 16 vs. 3 ng/ml, p = 0.007). Washout was depicted in 9/12 (75%) HCC, and 69/241 (29%) benign lesions (p <0.001). A total of 52/143 (36%) lesions ≥1 cm with arterial hyperenhancement showed washout (9 HCC and 43 benign lesions). In this subgroup, the specificity of washout for the diagnosis of HCC was 67%. Adding T1-w hypointensity raised the specificity to 100%. A serum AFP >15 ng/ml was associated with 95% specificity. CONCLUSION: Washout was observed in close to one-third of benign lesions, leading to an unacceptably low specificity for the diagnosis of HCC. The non-invasive diagnostic criteria proposed for cirrhotic patients cannot be extrapolated to patients with BCS. LAY SUMMARY: Washout on MRI is depicted in a significant proportion of benign nodules in patients with Budd-Chiari syndrome (BCS), limiting its value for the differentiation between benign and malignant lesions. Criteria proposed for the non-invasive diagnosis of hepatocellular carcinoma in patients with cirrhosis cannot be extrapolated to patients with BCS. Additional imaging findings and patient characteristics, including alpha-fetoprotein serum level, can help determine the probability of a nodule being HCC in patients with BCS.
引用
- Van Wettere M, Purcell Y, Bruno O, et al. Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome. J Hepatol. 2019. PMID: 30654065. doi:10.1016/j.jhep.2019.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。